Purpose: Excessive weight gain associated with sodium valproate (VPA) may predispose patients with epilepsy to other health problems such as insulin resistance. We prospectively evaluated the long-term impact of VPA monotherapy compared with lamotrigine (LTG) monotherapy on anthropometric and metabolic parameters in women with epilepsy. Our primary objective is to understand the underlying mechanism responsible for VPA-induced obesity. Methods: Sixty-six female patients with newly diagnosed or untreated epilepsy were included in the study. Thirty-four patients with VPA and thirty-two patients with LTG were treated for a period of one year in our center. Anthropometric and clinical data were collected at 5 time points: before, at 6th week, 3rd month, 6th month, 9th month and 12th month (last visit). Biochemical and hormonal data were collected 2 time points: before and last visit. Results: Subjects in the VPA group had significantly higher body weight than LTG-treated subjects (64.88 AE 3.25 vs. 58.28 AE 2.43, P < 0.001). HOMA-IR level was significantly increased (2.76 vs. 1.35, P < 0.05), and adiponectin levels were significantly lower in the VPA group (3.46 vs. 6.22, P < 0.05). Triglycerides levels were significantly increased (118 vs. 96, P < 0.05), and HDL-C levels were significantly lower in the VPA group. Both the VPA-treated group and the LTG-treated group showed no significant difference in term of total cholesterol, LDL-C, fasting blood glucose and serum leptin levels. Conclusions: Based on the findings of this study, we proposed that VPA induced hypoadiponectinemia which correlates significantly with insulin resistance. These two factors may be responsible for weight gain, possible by stimulating appetite. Valproic acid appears to be use cautionally in obese females with epilepsy.
Introduction
Sodium valproate (VPA) and lamotrigine (LTG) are the broadspectrum anticonvulsants drugs used in both generalized and partial seizures. Weight gain is a well-known adverse effect of VPA treatment occurring in up to 71% of exposed patients, although typically the rate is around 10% [1] . Weight gain is the most common reason for patients to discontinue VPA treatment [2] [3] [4] . In a study, 38% of VPA-treated patients gained more than 10% of their body weight compared with 8% of patients treated with LTG [5] .
Further, weight gain associated with VPA seems to be appetiterelated and not metabolic [6] . However, the real pathogenic mechanisms underlying VPA-induced weight increase is remain unclear. Reports in epileptic populations have shown that VPA is associated with hyperinsulinaemia, both in conjunction with and independent from changes in weight [7] [8] [9] . Various ideas regarding mechanisms behind the link between VPA-induced weight gain and insulin resistance (IR) have been suggested. The observation of hyperinsulinaemia in the lean patients taking VPA suggesting the role of factors others than excess adiposity in the pathogenesis of IR [8] . The adipocytokines such as leptin and adiponectin which are derived from adipose tissue could be involved in impairing insulin signaling and reduce GLUT4 gene expression.
The purpose of this study was to examine the changes in body weight and several biochemical and endocrine parameters in female epileptic patients receiving either VPA or LTG monotherapy. Secondary outcome was to explore the relation between adipocytokines and insulin resistance among VPA-treated patients.
Methods

Subjects
The present study was conducted at the department of Neurology, M.S. Ramaiah Memorial hospital, Bangalore, India, with the approval of local Ethics committee. Informed consent was obtained from all the subjects. All subjects gave consent to use non-hormonal contraception throughout the study and for at least 3 weeks after the last dose of study drug. The type of epilepsy was classified according to the recommendations of the International League Against Epilepsy (ILAE) [10] .
Subjects in the patient groups
The study was conducted in 66 newly diagnosed or untreated female epileptic patients. In untreated epileptic patients up to 2 weeks of treatment with any AED other than VPA or LTG is allowed prior to enrollment in the study. During the first two weeks, if a patient entered the study on an antiepileptic drug other than VPA or LTG, it should be tapered off within two weeks after the initiation of treatment with study drug. After this time period, only benzodiazepines may be used acutely (up to 24 h) for management of breakthrough seizures. Patients between the ages of 12 and 40 years were recruited into the study from October 2004 to May 2006. Brain magnetic resonance imaging or computed tomographic scans were interpreted as normal.
Urine pregnancy test was done on all patients at the time of screening. Any positive result was not eligible for study. Those who were followed up for fewer than 3 months or who discontinued drug treatment within 3 months of initiation, were excluded. Other exclusion criteria were breast feeding, body mass index (BMI) > 30 kg/m 2 , any history suggestive of clinically significant impairment of renal/hepatic dysfunction and currant abuse of alcohol or other substances. Other screening assessments included seizure frequency, vital signs, physical and neurological examinations and medical history.
Study protocol
It was an open label randomized comparative prospective study. Patients were randomly allotted into two groups, with 34 patients in VPA group and 32 patients in LTG group. All patients in both groups should received respective drugs as monotherapy for at least one year. All patients were followed for one year from time of inclusion. The intelligence levels were similar in both groups. Neither the behavior nor the cognitive therapies were implemented on our patients either before or during the study period.
Dosage and dosing
All patients in LTG group were initiated with LTG 25 mg once a day for 1st two weeks then 50 mg once a day for another 2 weeks followed by maintenance dose 200 mg twice a day. On the basis of clinical response the dose of LTG was titrated according to the dosing schedule to a maximum of 550 mg/day. If a decision was made to discontinue LTG therapy, a step-wise reduction of dose over at least 3 weeks was recommended. For all patients randomized to VPA group were received VPA in a dose of 750 mg/day for the first week and escalating to 1000 mg/day in next week. Target maintenance dose for VPA was 1000-2000 mg/ day.
Initial screening examinations
The patients with epilepsy who met the inclusion criteria mentioned above were clinically and physically examined by two neurologists, and interviewed by the first author. Anthropometric data such as weight, height were measured. All the patients were evaluated at inclusion, at the end of 6th week, at the end of 3rd month, sixth month, ninth month and 12th month. During each visit all the patients underwent complete neurological examination, review of medical history, adverse events or reactions, compliance, concomitant medications were checked.
Collection of anthropometric and clinical data
Age, gender, BMI, seizure type, duration of illness, age at onset, dose of drug utilized, response to antiepileptic therapy, and family history were recorded clearly in a designed form. The height was measured to the nearest 0.1 cm with the wall-mounted statiometer. The weight was measured to the nearest 0. [11] . At the end of study, we categorized the patients according to their respective BMI (baseline vs. last visit at 12th month) in the both groups.
Collection of biochemical parameters
Blood samples were collected following 12hr overnight fast. The following parameters were measured using commercially available radioimmunoassay kits: fasting insulin, fasting glucose, adiponectin, leptin and lipid profiles at the time of inclusion and at the end of study (12th month). Serum lipid profiles were estimated using an automated analyser (advia 1800 analyser, Siemens, Germany). Serum insulin were estimated by Advia Centaur CP (Siemens diagnostics) insulin immunoassay with sensitivity of 0.5 mIU/L and assay range is 0.5-300 mIU/L. Intraassay and interassay coefficients of variation were 2.4% and 1.8% respectively. Serum leptin and adiponectin were estimated using commercially available ELISA kits (Ani Biotech Orgenium laboratories, Finland). The glucose oxidase peroxidase method was used for measurements of plasma glucose (Siemens advia 1800). The insulin resistance was estimated using the homeostasis model assessment for insulin resistance (HOMA-IR); fasting insulin (mIU/ L) Â fasting glucose (mg/dl)/405 [12] . Insulin resistance is defined as level of HOMA-IR greater than 2.5 [13] . At the end of study, all of the VPA-treated patients were further classified into two cohorts (HOMA-IR > 2.5 vs. HOMA-IR 2.5)
Statistical analysis
SPSS 11.0 software was used for analysis of data, with twotailed, significant level at P < 0.05. Data is expressed as mean AE SD for quantitative parametric measures in addition to median (range) for quantitative nonparametric measures and both number and percentage for categorized data. Student's t-test was used for comparison between two independent mean groups for parametric data. Wilcoxon Rank Sum test and Mann-Whitney U test for nonparametric data. Correlation analyses were conducted using Spearman or Pearson correlation coefficients depending once again, on the distribution of the variables.
Results
The basic characteristics of the study population are depicted in Tables 1 and 2 . The study profile is outlined in Fig. 1 . The mean weight was significantly higher in VPA-treated patients than in LTG-treated patients (P < 0.001) (Fig. 2) . The gained in weight in VPA-treated patients were observed within the first 3 months of therapy and peaking by the sixth month (Fig. 2 ). According to BMI categories, patients in VPA treated group showed significantly higher weight gain in all three arms (P < 0.01) ( Table 3 ). The mean BMI was also higher in VPA-treated patients in all three arms as compared to LTG-treated patients (P < 0.05) ( Table 3) . At the end of one year, two patients in normal weight arm became overweight, one became obese and four patients who were overweight became obese in VPA group, while in LTG group only one patient in overweight arm became obese. Three patients who were underweight in VPA group, two remain underweight at the end of study (Table 3) . We observed that the risk of obesity was magnified in those VPA-treated patients who had a greater weight at the start of treatment.
In comparisons between VPA and LTG groups, FINS and HOMA-IR were significant higher in all the three arms (P < 0.05) ( Table 3 ). The median HOMA-IR values were progressively increased from normal weight to obese in VPA group (Table 3) . Fasting serum HDL cholesterol levels were significant lower in the overweight (P < 0.05) and obese arms (P < 0.05) in the VPA group (Table 3) . The serum triglycerides concentrations were significantly higher in all three arms of VPA-treated patients (P < 0.05) ( Table 3 ). There were no significant differences in the total cholesterol levels or in the LDL cholesterol levels between the VPA-treated patients and the LTG-treated patients. Mean adiponectin level was significantly lower in the VPA-treated patients compared to LTG-treated patients in all the three arms (P < 0.05) ( Table 3 ). There was no significant difference in the mean serum leptin level between the VPA-treated patients and LTG-treated patients, but serum leptin levels were non-significantly higher in the obese VPA-treated patients than the lean VPA-treated patients after 1 year of therapy.
Among the VPA-treated patients, 11 (37%) patients developed insulin resistance (HOMA-IR > 2.5) during the course of therapy. Two of these 11 patients came from normal weight category, four from overweight and five from obese category. For women taking LTG, two patients who had insulin resistance before starting therapy, they became insulin sensitive during the course of therapy after one year.
All of the VPA-treated patients at the end of study period (1-year) were classified into two cohorts, HOMA-IR > 2.5 and HOMA-IR 2.5. The measurements of biochemical indexes for both the cohorts were shown in Table 4 . The correlation coefficient was used to capture the linear association between HOMA-IR and these biochemical markers. The HOMA-IR > 2.5 significantly correlated with body weight, BMI, FINS and adiponectin levels. There was no correlation between HOMA-IR > 2.5 with VPA dose, FBG, lipid profile and leptin levels ( Table 5 ).
Discussion
Valproic acid or lamotrigine are the drug of choice for a wide variety of epileptic seizures and syndromes because of their broad spectrum of activity. Weight gain is a common adverse effect of valproic acid therapy, occurring in up to 71% of patients [4, 7, 14, 16] . In recent years, many clinical studies have revealed that the occurrence of weight gain is more prevalent in epileptic females treated with VPA as compared to VPA-treated males [4, 8, 17] . From the analysis of these data, in female patients, a further risk factor is the younger age: the increase in body weight appears to occur more frequently in post-pubertal girls taking VPA than prepubertal girls [17] [18] [19] . In our study, all the patients were postpubertal female patients. Furthermore, our results demonstrated that the occurrence of weight gain was more prevalent in VPAtreated patients than LTG-treated patients. Total 57% (19/34) women who were on VPA therapy, gained weight (range, 1-10 kg) as compared to 25% (8/32) (range, 1-3 kg) in the LTG-treated patients. In our study, the VPA-treated patients who had higher Values are median and range, percentage; VPA, valproate; LTG, lamotrigine. pre-treatment weight were more likely to put on weight during course of therapy. VPA-treated patients who were in overweight and obese arms were gained higher weight than patients of normal weight or underweight patients. Before valproic acid therapy, 23% of the patients were overweight, this percentage rose to 32% after treatment (P = 0.06). A total of 32% and 47% of patients were classified as obese before and after VPA therapy, respectively (P = 0.03). These finding are correlates with other studies [17, 18] .
Our results are in agreement with those of Elaine et al. [17] ; who showed that overweight before starting therapy was a predictor of high BMI at the end of the study (P < 0.0002). In contrast, Goldberg-stern et al. [20] showed that administration of valproic acid had no adverse effect on body weight and insulin resistance markers over an average follow-up of 3.2 years. However, in this study the mean age at the time of initiation of VPA was 11.75 AE 3.37. Only 41% patients were taken from post-pubertal age group. Espinosa et al. [21] found that the initiation of VPA therapy before age 12 years (prepubertal stage) was not associated with weight gain. Similarly, in the study of El-Khayat et al. [19] ; girls treated with VPA at different stages of puberty, observed significant weight gain only in those in the post-pubertal stage (57% compared to 25% in prepubertal patients, P = 0.03). We observed excellent seizure control with complete disappearance of seizures after 2 months of monotherapy in all patients in both groups. Thus, severity and frequency of seizures were similar in the both groups. However, 85-90% patients remained seizure free until the end of the study. Only one patient in the VPAtreated group and four patients in the LTG-treated group required additional anticonvulsant medication during the study. Therefore, they were excluded from the study. In the VPA-treated group, 3 patients were withdrawal from the study, two due to excessive weight gain and one due to hair loss. Only one patient was withdrawal from the LTG-treated group due to her personal region. None of the patient in the LTG-treated group developed rash.
Eleven patients (37%) fulfilled the criteria for the insulin resistance (HOMA-IR > 2.5) in the VPA-treated patients. The presence of insulin resistance in the lean VPA patients (18%) implies that the insulin resistance seen in overweight and obese VPA patients is not induced by weight gain. It is possible that the development of insulin resistance may be one of the factors leading to weight gain in some patients [7, 18, 22] .
In the present study, BMI and FINS levels were positively and adiponectin levels negatively correlated with insulin resistance in the VPA-treated patients. Both the obese patients taking either VPA or LTG had higher serum concentrations of leptin than did the respective lean patients. These data are consistent with the results previously reported by Pylvanen et al. [8] ; that serum leptin levels did not differ between obese patients taking VPA and obese control subjects, suggesting that leptin activation is similar in both groups. It was expected in our study that obesity associated with high serum leptin levels.
In general, high serum insulin levels and obesity are associated with unfavorable changes in the serum lipid profile. Our results showed significantly decreased serum HDL-C and increased triglyceride concentrations in the VPA-treated patients which are consistent with other studies [22, 23] . This implies that VPAtreated patients have a higher risk for cardiovascular diseases than the LTG-treated patients.
The exact pathogenic mechanisms of weight gain in patients taking valproic acid remains unclear, but it is most likely multifactorial. Body weight is regulated centrally and peripherally by various neuropeptides and cytokines. These regulatory substances include adiponectin, leptin, ghrelin, visfatin. Adiponectin and leptin are potential regulators of glucose and fat metabolism during VPA-therapy [24] . Leptin is a satiety hormone while ghrelin is a hunger hormone, both acts on the receptors in the arcuate nucleus of the hypothalamus via gamma-aminobutyric acid (GABA) to regulate appetite to achieve energy homeostasis [25] .
In VPA-induced obesity, drug may be altered the sensitivity of leptin receptors which may result in increased leptin levels which fails to control hunger and modulate the weight. Many clinical studies have reported increased serum levels of leptin in children and adults who gain weight during VPA treatment [15, 26] . Kanemura et al. [6] reported that increased consumption of food Table 3 Clinical characteristics and biochemical index in women with epilepsy at the end of study (1-year and energy-rich beverages because of an increased appetite and abnormal thirst has been implicated for weight gain induced by VPA. These weight changes are reversible with behavior therapy without discontinuation of VPA. Adiponectin is a protein which regulates the glucose and fatty acid oxidation. Numerous studies demonstrate that adiponectin gene expression inversely correlates with body weight. Therefore, it is reasonable to speculate that VPAinduced insulin resistance might occur through the down regulation of adiponectin. In vitro, VPA directly inhibits adiponectin gene expression in differentiated adipocytes [27] , but from the available literature, we did not get any clinical data regarding whether VPA alters adiponectin gene expression in human subjects also. If we hypothesized that VPA per se was the reason behind hypoadiponectinemia in our patients, because there was significant difference in levels between VPA and LTG groups having a comparable BMI. Therefore, we propose the role of VPA in inducing hypoadiponectinemia in obese epileptic patients. Both low adiponectin levels and insulin resistance were found in bipolar patients on VPA therapy [28] . The significant negative correlation found between insulin resistance and hypoadiponectin in our study support this. Visfatin is a hormone which has insulin-mimetic effects and lowers plasma glucose levels [24, 29] . Probably, low glucose levels stimulate eating through an effect on glucose-responsive neurons in the medial hypothalamus, which, in turn, reduces the efferent inhibitory output to the lateral hypothalamus. Recently, Rakitin et al. [30] showed that intravenous VPA therapy was associated with acute glucose-lowering effect without significant changes in serum insulin and C-peptide levels during oral glucose tolerance test in patients with newly diagnosed epilepsy. This study suggested that hypothalamus ATP-sensitive potassium channels (K ATP ) play a significant role in the central regulation of glucose homeostasis. Activation of these channels within the medial hypothalamus is sufficient to decrease the blood glucose levels via the suppression of glucose production. We found no significant difference in fasting glucose between VPA and LTG groups having similar BMI. Interestingly, Meral et al. [22] showed that visfatin levels were significantly increased (P < 0.001) and adiponectin levels were significantly lower (P < 0.001) in the VPA-treated group as compared to control group.
The main limitation of the current study is the small sample size and further dropout of patients during long follow-up period. The major reasons for dropout are excessive weight gain during therapy, financial constraints affecting ability to buy drugs over long period of time and certain females stopped drugs and followup after marriage due to stigma attached to the disease. We did not monitor feeding habits of the patients during VPA medication. We did not measure serum visfatin levels. Despite these limitations, our results provide important information which improves the understanding of VPA-associated alteration of metabolic profile among patients.
Due to small sample size, we cannot make definitive conclusion. Based on the findings of our study we proposed the following underlying pathophysiology mechanisms that responsible for VPAinduced weight gain, possibly by stimulating appetite (Fig. 3) . However, this problem has been not observed in all patients. Future research should be based on large sample size and a close observation of eating habits. A quantify the calorie intake through a food-frequency questionnaire, and levels of physical activity in these patients during VPA therapy. The programmed behavior therapy may be considered before initiation of VPA therapy in one group of patient's give better understanding regarding this. VPA induced weight gain is the important risk factor for the development of other complications like diabetes, dyslipidemia, metabolic syndrome and nonalcoholic fatty liver disease. Therefore, pre-treatment weight should be taken into consideration when choosing this drug for female patients and BMI should be checked regularly during each follow-up visit. Drug induced weight gain is the great concern for patients and their clinicians because it not only affects body image and self-confidence but also impair compliance. VPA is a very important drug in neurology and psychiatry, but VPA-associated weight gain is still not wellunderstood, and further well-designed human studies are needed to better understand the relationship between weight gain and metabolic disturbances, and to enhance our knowledge about this amazing drug. 
